1. Impact of tamoxifen therapy on fertility in breast cancer survivors
Lisa M. Shandley, B.A., Jessica B. Spencer, M.D., M.Sc., Amy Fothergill, M.P.H., Ann C. Mertens, Ph.D., Amita Manatunga, Ph.D., Elisavet Paplomata, M.D., Penelope P. Howards, Ph.D. 
Fertility and Sterility 
Volume 107, Issue 1, Pages e5 (January 2017)
DOI: /j.fertnstert
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Unadjusted Kaplan-Meier curves of time to first child after breast cancer diagnosis by tamoxifen status in a cohort of young breast cancer survivors, censored at time of hysterectomy, bilateral oophorectomy, tubal ligation, or study interview. (A) Includes all breast cancer survivors. (B) Restricted to women who were childless at diagnosis. (C) Restricted to women who had not yet met their reproductive goals at the time of diagnosis. (D) Restricted to women who were estrogen/progesterone receptor positive. (Note: Women who took tamoxifen and women with documented hormone receptor status in medical records were considered to be hormone-receptor positive.) (E) Tamoxifen group versus women who were hormone-receptor (ER/PR) negative. (Note: Breast cancer survivors who are estrogen/progesterone receptor negative are generally not candidates for adjuvant tamoxifen.) (F) Excludes women who reported their period stopping during cancer treatment and never returning.
Fertility and Sterility  , e5DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

3. Supplemental Figure 1
Unadjusted Kaplan-Meier curve of time to first child after breast cancer treatment by tamoxifen status. Time at risk began when the survivor finished breast cancer treatment or tamoxifen use. Women who became pregnant while taking tamoxifen are not included in this analysis.
Fertility and Sterility  , e5DOI: ( /j.fertnstert )
Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions